BI
VERV

BVF Inc’s Verve Therapeutics VERV Stock Holding History

BVF Inc’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,904,050
Closed -$31.6M – 51
2025
Q1 		$31.6M Hold
6,904,050
– – 1.29% 17
2024
Q4 		$38.9M Buy
6,904,050
+6,254,050
+962% +$35.3M 1.32% 18
2024
Q3 		$3.15M Hold
650,000
– – 0.09% 45
2024
Q2 		$3.17M Hold
650,000
– – 0.09% 46
2024
Q1 		$8.63M Hold
650,000
– – 0.24% 42
2023
Q4 		$9.06M Hold
650,000
– – 0.23% 50
2023
Q3 		$8.62M Hold
650,000
– – 0.23% 47
2023
Q2 		$12.2M Hold
650,000
– – 0.34% 43
2023
Q1 		$9.37M Hold
650,000
– – 0.34% 50
2022
Q4 		$12.6M Hold
650,000
– – 0.53% 47
2022
Q3 		$22.3M Buy
+650,000
New +$20.7M 0.92% 36

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BVF Inc's VERV Position: Q2 2025 in Review

BVF Inc sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 6,904,050 shares — an estimated $31.6M sold.

BVF Inc first reported a position in VERV in Q3 2022 and held it in 11 quarters. The position peaked at $38.9M in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • BVF Inc reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BVF Inc sold 6,904,050 Verve Therapeutics shares in Q2 2025, an estimated $31.6M.
  • BVF Inc first reported a position in Verve Therapeutics in Q3 2022 and held it in 11 quarters.
  • BVF Inc's Verve Therapeutics position peaked at $38.9M in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on BVF Inc's 13F filing for Q2 2025, filed 14 Aug 2025.